Skip to main content
INO
NASDAQ Life Sciences

Inovio Q3: $49.2M Loss, $48.4M Cash, Going Concern Pushed to Late Q4 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.47
Mkt Cap
$149.926M
52W Low
$0.563
52W High
$2.72
52W Position info
161% above low
Off High info
46% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

INO has more than doubled off its 52-week low of $0.563.

Summary

Inovio's Q3 loss of $49.2 million was mostly a $26.9 million non-cash warrant remeasurement; with $48.4 million in cash plus the $80.5 million November raise, management now sees funding into late Q4 2027, though going-concern doubt persists.


Key Events · Earnings and Guidance · INO

  • Q3 Loss Driven by Non-Cash Warrant Mark

    Net loss of $49.2 million for the quarter included a $26.9 million non-cash change in fair value of warrant liabilities; nine-month net loss was $74.9 million versus $88.7 million a year earlier.

  • Cash Position and Runway Extended

    Cash, cash equivalents and short-term investments were $48.4 million at September 30, 2026, with a $38.0 million working capital deficit; including the $80.5 million November offering and $10.9 million of subsequent warrant exercises, funding is expected into late Q4 2027.

  • Going Concern Doubt Remains

    Management states substantial doubt exists about the ability to continue as a going concern beyond the fourth quarter of 2027 without additional financing.

  • Warrant Liability Swells to $70.0M

    The liability-classified warrant balance rose to $70.0 million at September 30, 2026 from $29.1 million at December 31, 2025, reflecting new July and April 2026 warrants plus remeasurement — a non-cash item, not new cash obligations.


Analysis · INO · Life Sciences

The quarter's headline loss is mostly accounting noise: $26.9 million of the $49.2 million net loss is a non-cash mark-to-market on liability-classified warrants, driven by the share price, not by cash leaving the business or new dilution. What matters is the runway. With $48.4 million of cash and short-term investments at September 30 plus the $80.5 million November offering and $10.9 million of subsequent warrant exercises, management now says funding lasts into late Q4 2027 — later than the late Q1 2027 it flagged last quarter. Against that, the company still carries a $38.0 million working capital deficit and a $70.0 million warrant liability, and it must fund the VOCERYQ launch, priced at roughly $115,000 per dose ($460,000 for the four-dose series), plus a confirmatory study whose draft protocol is due to the FDA by end-2026. The going-concern warning remains, so another raise is likely before the runway ends.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, INO was trading at $1.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $149.9M. The 52-week trading range was $0.56 to $2.72. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

INO - Latest Insights

INO
Nov 10, 2026, 4:05 PM EST
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.46
Real-time Price: $1.41 info
Change: -$0.050 (-3%) info
Market Cap: $152.511M info
INO
Nov 09, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.37
Real-time Price: $1.41 info
Change: +$0.040 (+3%) info
Market Cap: $152.511M info
INO
Nov 06, 2026, 4:30 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $1.21
Real-time Price: $1.41 info
Change: +$0.200 (+17%) info
Market Cap: $152.511M info
INO
Nov 05, 2026, 11:19 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1.23
Real-time Price: $1.41 info
Change: +$0.1806 (+15%) info
Market Cap: $152.511M info
INO
Nov 05, 2026, 7:46 PM EST
Filing Type: FWP
Importance Score:
7
Price at Filing: $1.15
Real-time Price: $1.41 info
Change: +$0.2592 (+23%) info
Market Cap: $152.511M info